ZNTL Company Profile and Key Details

Short-term trend indicators are bearishly aligned (SMA20 0.94%, SMA50 6.62%, SMA200 48.11%). The stock’s 14-day RSI is 50.68 (neutral), while the ATR of 0.22 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -37.47% below its high and over 144.55% above its low. Average 10-day trading volume of 2.29 million shares is in line with the 3-month average of 2.19 million, indicating normal recent market interest.

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) closed at $4.85 USD, gaining $0.24 (5.21%) from the previous close of $4.61. The stock is currently mid-range between its 52-week high and low $1.13 and $6.95. With a market capitalization of about $345.25 million, Zentalis Pharmaceuticals, Inc. is classified as a small-cap and shows higher-than-market volatility (beta ~1.98). Key stats such as the average daily volume over the past year has been around 2.22 million shares, in line with its 52-week average. Headquartered in San Diego, CA, Zentalis Pharmaceuticals, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Julia Marie Eastland, the company employs approximately 106 people and listed since April 03, 2020. Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering and developing clinically differentiated, novel small molecule therapeutics targeting fundamental biological pathways of cancer.

Zentalis Pharmaceuticals, Inc. has 72.14 million shares outstanding. The public float is 49.98 million shares, elevated short interest at 7.76% of float. This equals 4.48 million shares. The short ratio is 5.73 days. Institutional investors hold 80.44% of the float. Insiders own 22.84%. WALTERS GROUP holds 13.51 million shares, Matrix Capital Management Company, LP has 6.46 million shares and SUN ANTHONY Y has 1.18 million shares. Over the past six months, insider transactions show net selling. They sold 55.37 thousand shares across 9 transactions.

Zentalis Pharmaceuticals, Inc. generated EPS of -$2.08 over the past year. Five-year average earnings growth is -12.89%. Wall Street analysts project EPS growth of 12.28% annually over the next five years. Analyst sentiment is neutral. Analyst rating data shows there are 0 Strong Buy ratings, 2 Buy ratings, 2 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $10.00 to $4.00. The high target offers 106.19% upside. The low target suggests -17.53% downside. The mean target is $6.25. This offers 28.87% upside. Zentalis Pharmaceuticals, Inc. earnings surprise history is a mixed track record. The quarter that ended May 12, 2026, missed forecasts by 2.04%. The prior quarter beat by 19.51%. Over the last six quarters, Apple has recorded several small beats. These include -12.0% in March 26, 2025.

Zentalis Pharmaceuticals, Inc. trades at a P/E ratio of -2.93, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 1.95 suggesting the stock is closer to book value. The P/FCF stands at -2.88, also below market averages.

Zentalis Pharmaceuticals, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$0.05. This means the shares are trading below this model’s fair value.

Our AI price prediction model suggests that Zentalis Pharmaceuticals, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -12.99%, with price expected at $4.22 by July 13, 2026, within a range of $3.99 to $4.45 3-Month Outlook: Projected rise of 87.84%, reaching $9.11 by September 25, 2026, with a range of $9.01 to $9.23. 1-Year Outlook: Projected gain of 250.93%, with price at $17.02 by June 29, 2027, within a range of $4.78 to $24.24.

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) shares are up 112.59% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Zentalis Pharmaceuticals, Inc. trading at a premium to the broader market with a P/E of -2.93. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $34.76, suggesting 616.7% upside. Our AI forecast model points to short-term weakness (-12.99% over two weeks), a medium-term rise (87.84% over three months), and a longer-term gain (250.93% over one year), with expected trading ranges indicating moderate volatility.